CN111035716A - 一种治疗感冒后咳嗽寒饮伏肺证的中药颗粒 - Google Patents
一种治疗感冒后咳嗽寒饮伏肺证的中药颗粒 Download PDFInfo
- Publication number
- CN111035716A CN111035716A CN202010030454.9A CN202010030454A CN111035716A CN 111035716 A CN111035716 A CN 111035716A CN 202010030454 A CN202010030454 A CN 202010030454A CN 111035716 A CN111035716 A CN 111035716A
- Authority
- CN
- China
- Prior art keywords
- filtrate
- mixing
- weight
- carrying
- cold
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010011224 Cough Diseases 0.000 title claims abstract description 64
- 239000003814 drug Substances 0.000 title claims abstract description 61
- 210000004072 lung Anatomy 0.000 title claims abstract description 34
- 239000008187 granular material Substances 0.000 title claims abstract description 32
- 239000012530 fluid Substances 0.000 title claims abstract description 14
- 244000037364 Cinnamomum aromaticum Species 0.000 claims abstract description 32
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 claims abstract description 32
- 241000218671 Ephedra Species 0.000 claims abstract description 31
- 244000274050 Platycodon grandiflorum Species 0.000 claims abstract description 26
- 241001180876 Saposhnikovia Species 0.000 claims abstract description 21
- 244000303040 Glycyrrhiza glabra Species 0.000 claims abstract description 19
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims abstract description 19
- 235000006753 Platycodon grandiflorum Nutrition 0.000 claims abstract description 18
- 235000006484 Paeonia officinalis Nutrition 0.000 claims abstract description 16
- 240000006079 Schisandra chinensis Species 0.000 claims abstract description 16
- 235000008422 Schisandra chinensis Nutrition 0.000 claims abstract description 16
- 240000007641 Spergula rubra Species 0.000 claims abstract description 13
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 claims abstract description 13
- 235000011477 liquorice Nutrition 0.000 claims abstract description 13
- 239000000706 filtrate Substances 0.000 claims description 299
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 56
- 238000002156 mixing Methods 0.000 claims description 40
- 239000000843 powder Substances 0.000 claims description 31
- 238000001914 filtration Methods 0.000 claims description 27
- 208000011580 syndromic disease Diseases 0.000 claims description 27
- 238000000605 extraction Methods 0.000 claims description 19
- 241000736199 Paeonia Species 0.000 claims description 15
- 244000248557 Ophiopogon japonicus Species 0.000 claims description 9
- 239000003651 drinking water Substances 0.000 claims description 9
- 235000020188 drinking water Nutrition 0.000 claims description 9
- 239000012452 mother liquor Substances 0.000 claims description 9
- 239000000341 volatile oil Substances 0.000 claims description 9
- 235000006751 Platycodon Nutrition 0.000 claims description 8
- 229930189914 platycodon Natural products 0.000 claims description 8
- 238000001035 drying Methods 0.000 claims description 7
- 229930195210 Ophiopogon Natural products 0.000 claims description 6
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 claims description 5
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 claims description 5
- 229940010454 licorice Drugs 0.000 claims description 5
- 238000010992 reflux Methods 0.000 claims description 5
- 238000004821 distillation Methods 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 4
- 239000002994 raw material Substances 0.000 claims description 4
- 229920001353 Dextrin Polymers 0.000 claims description 3
- 239000004375 Dextrin Substances 0.000 claims description 3
- 235000019425 dextrin Nutrition 0.000 claims description 3
- 201000009240 nasopharyngitis Diseases 0.000 claims description 3
- 230000000717 retained effect Effects 0.000 claims description 3
- 241000202726 Bupleurum Species 0.000 claims description 2
- 238000000227 grinding Methods 0.000 claims 2
- 235000017443 Hedysarum boreale Nutrition 0.000 claims 1
- 235000007858 Hedysarum occidentale Nutrition 0.000 claims 1
- 238000002481 ethanol extraction Methods 0.000 claims 1
- 239000001947 glycyrrhiza glabra rhizome/root Substances 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 abstract description 8
- 240000002948 Ophiopogon intermedius Species 0.000 abstract 1
- 244000170916 Paeonia officinalis Species 0.000 abstract 1
- 238000011282 treatment Methods 0.000 description 17
- 206010016807 Fluid retention Diseases 0.000 description 10
- 238000003745 diagnosis Methods 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- 208000024891 symptom Diseases 0.000 description 9
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 230000001717 pathogenic effect Effects 0.000 description 5
- 208000000059 Dyspnea Diseases 0.000 description 4
- 206010013975 Dyspnoeas Diseases 0.000 description 4
- 206010062717 Increased upper airway secretion Diseases 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 208000026435 phlegm Diseases 0.000 description 4
- 206010063659 Aversion Diseases 0.000 description 3
- 206010061245 Internal injury Diseases 0.000 description 3
- 208000003251 Pruritus Diseases 0.000 description 3
- 206010057190 Respiratory tract infections Diseases 0.000 description 3
- 230000002411 adverse Effects 0.000 description 3
- 230000007812 deficiency Effects 0.000 description 3
- 206010013781 dry mouth Diseases 0.000 description 3
- 230000014759 maintenance of location Effects 0.000 description 3
- 210000003800 pharynx Anatomy 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 230000000630 rising effect Effects 0.000 description 3
- 208000013220 shortness of breath Diseases 0.000 description 3
- 229920000858 Cyclodextrin Polymers 0.000 description 2
- 206010028748 Nasal obstruction Diseases 0.000 description 2
- 206010036790 Productive cough Diseases 0.000 description 2
- 206010039101 Rhinorrhoea Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 235000020965 cold beverage Nutrition 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 230000007803 itching Effects 0.000 description 2
- 208000010753 nasal discharge Diseases 0.000 description 2
- 230000000241 respiratory effect Effects 0.000 description 2
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 2
- 208000024794 sputum Diseases 0.000 description 2
- 210000003802 sputum Anatomy 0.000 description 2
- 230000035922 thirst Effects 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 210000001835 viscera Anatomy 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 206010065563 Eosinophilic bronchitis Diseases 0.000 description 1
- 208000004852 Lung Injury Diseases 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 208000037656 Respiratory Sounds Diseases 0.000 description 1
- 208000032140 Sleepiness Diseases 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 1
- 206010069363 Traumatic lung injury Diseases 0.000 description 1
- 206010047482 Viral upper respiratory tract infection Diseases 0.000 description 1
- 208000031975 Yang Deficiency Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000000954 anitussive effect Effects 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000001387 anti-histamine Effects 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 229940124584 antitussives Drugs 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 description 1
- 230000006837 decompression Effects 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 1
- 208000017574 dry cough Diseases 0.000 description 1
- 238000005265 energy consumption Methods 0.000 description 1
- 208000021302 gastroesophageal reflux disease Diseases 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 239000000938 histamine H1 antagonist Substances 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 229960003447 pseudoephedrine hydrochloride Drugs 0.000 description 1
- BALXUFOVQVENIU-KXNXZCPBSA-N pseudoephedrine hydrochloride Chemical compound [H+].[Cl-].CN[C@@H](C)[C@@H](O)C1=CC=CC=C1 BALXUFOVQVENIU-KXNXZCPBSA-N 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 206010037833 rales Diseases 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 208000020029 respiratory tract infectious disease Diseases 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 230000037321 sleepiness Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/17—Gnetophyta, e.g. Ephedraceae (Mormon-tea family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/238—Saposhnikovia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/34—Campanulaceae (Bellflower family)
- A61K36/346—Platycodon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/36—Caryophyllaceae (Pink family), e.g. babysbreath or soapwort
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/57—Magnoliaceae (Magnolia family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/65—Paeoniaceae (Peony family), e.g. Chinese peony
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/736—Prunus, e.g. plum, cherry, peach, apricot or almond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/79—Schisandraceae (Schisandra family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/888—Araceae (Arum family), e.g. caladium, calla lily or skunk cabbage
- A61K36/8888—Pinellia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8968—Ophiopogon (Lilyturf)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明涉及一种治疗感冒后咳嗽寒饮伏肺证的中药颗粒,可有效解决寒饮伏肺型感冒后咳嗽患者的治疗用药问题;该发明由重量份的:麻黄15‑31、桂枝15‑29、桔梗15‑31、麦冬15‑30、芍药12‑21、甘草12‑20、清半夏11‑22、五味子10‑16、乌梅10‑15、银柴胡9‑15、防风9‑14制成。解决的技术方案是将处方分成麻黄,桂枝、防风,桔梗、麦冬、芍药、甘草、五味子清半夏、乌梅、银柴胡3个药物成分组进行提取,制得β‑环糊精包合物A和浸膏细粉A;将β‑环糊精包合物A和浸膏细粉A混合制成颗粒剂,即得治疗感冒后咳嗽寒饮伏肺证的中药颗粒。本发明配伍合理,制备方法科学,疗效确切,无毒副作用,具有较高的经济和社会效益。
Description
技术领域
本发明涉及医药,特别是一种治疗感冒后咳嗽寒饮伏肺证的中药颗粒及其应用。
背景技术
感冒好了,咳嗽却经常反复,经久不愈,严重影响人的生活质量。感冒后咳嗽其实是一种常见的呼吸道疾病,在中国医师协会呼吸医师分会2019年会上,同济大学附属同济医院呼吸与危重症科邱忠民教授提到:感冒后咳嗽相当常见,2016年中国的一项流行病学研究表明,亚急性咳嗽患者中约38%病因为感冒后咳嗽,高于第二和第三之和。这一现象在基层医院尤为突出,仅2011年一项临床研究调查了1007例二甲医院的患者,发现病因为感冒后咳嗽的占55%之多。
感冒后咳嗽在西医学上定义为急性呼吸道感染后,感染本身急性期症状消失,咳嗽仍然迁延不愈持续3~8周。原称为感冒后咳嗽,指病毒性上呼吸道感染后引起的迁延性咳嗽。但临床发现部分细菌和典型病原体呼吸道感染后,也可引起相似表现,后改为感染性咳嗽,定义较感冒后咳嗽更广。
《素问》中记载:“皮毛者,肺之合也,皮毛先受邪气,邪气以从其合也。其寒饮食入胃,从肺脉上至于肺,则肺寒,肺寒则外内合邪,因而客之,则为肺咳。”感冒后咳嗽在治疗上,中医的辨证尤为重要。一般认为,新近发生的在表属实;迁延不愈,伤及肺肾的在里属虚,感冒后咳嗽发于感冒之后,多是虚证。对感冒后咳嗽,西医尚缺乏公认有效的药物,常用的中枢性镇咳药和抗组胺H1受体拮抗剂仅是对症治疗,对部分患者有效,可能导致思睡、口干、食欲减退、恶心、便秘等副反应,停药后咳嗽容易复发,而抗生素治疗往往无效,重症者吸入糖皮质激素治疗亦反复发作,且副作用较大,限制了其临床应用。
因此,深入开展感冒后咳嗽的中药治疗与新药研究开发对于提高临床防治水平和提高感冒后咳嗽的临床疗效具有重要意义,治疗感冒后咳嗽的药物上的改进是目前亟需解决的问题。
三、发明内容
针对上述情况,为解决现有技术之缺陷,本发明之目的就是提供一种治疗感冒后咳嗽寒饮伏肺证的中药颗粒,可有效解决感冒后咳嗽寒饮伏肺证的治疗用药问题。
本发明解决的技术方案是,该中药颗粒是由麻黄、桂枝、桔梗、麦冬、芍药、甘草、清半夏、五味子、乌梅、银柴胡、防风制成;各种原料药的重量份为:麻黄15-31、桂枝15-29、桔梗15-31、麦冬15-30、芍药12-21、甘草12-20、清半夏11-22、五味子10-16、乌梅10-15、银柴胡9-15、防风9-14;其原料药的重量可以为:麻黄15-31g、桂枝15-29g、桔梗15-31g、麦冬15-30g、芍药12-21g、甘草12-20g、清半夏11-22g、五味子10-16g、乌梅10-15g、银柴胡9-15g、防风9-14g。
该中药颗粒的制备方法为:将麻黄粉碎成过20目筛的粗粉,加入麻黄8倍重量的pH为3.6的体积浓度为30%的乙醇溶液,65℃闪式提取3.3min,过滤,得药渣a和滤液a,备用;将桂枝、防风混合,粉碎成过20目筛的粗粉,加入桂枝、防风总重量8.7倍量的饮用水蒸馏4.8h,收集挥发油A备用,剩余蒸馏母液部分过滤得药渣b及滤液b备用;将桔梗、麦冬、芍药、甘草、五味子混合,粉碎成过20目筛的粗粉,加入体积浓度为65%的乙醇83℃回流提取2次,每次加入体积浓度为65%的乙醇的量为桔梗、麦冬、芍药、甘草、五味子总重量的7.6倍量,过滤,合并两次滤液,得药渣c及滤液c备用;将清半夏、乌梅、银柴胡及药渣a、药渣b、药渣c混合,加入清半夏、乌梅、银柴胡总重量8.8倍量的质量浓度为1.6%的纤维素酶溶液及清半夏、乌梅、银柴胡总重量5.8倍量的质量浓度为1.9%的果胶酶溶液,45℃浸泡50min,53℃酶解2.2h,94℃回流提取2.3h,过滤,得药渣d和滤液d备用;将药渣d加入清半夏、乌梅、银柴胡总重量6.1倍量的体积浓度为50%的乙醇76℃回流提取1.6h,过滤,弃去药渣,得滤液e备用;将滤液a以1mol/L的NaOH溶液调节pH至6.7,过滤,得滤液f,将滤液f与滤液b、滤液d合并,55℃减压浓缩至50℃时比重为1.19-1.26的浸膏,得浸膏Ⅰ,备用;将滤液c与滤液e合并,52℃减压回收乙醇,56℃减压浓缩至50℃时比重为1.21-1.29的浸膏,得浸膏II,备用;将浸膏Ⅰ、浸膏II合并混匀,50℃减压干燥,粉碎,得浸膏细粉A,备用;将挥发油A与挥发油A3.9倍重量的β-环糊精研磨包合,减压干燥,粉碎成细粉,得β-环糊精包合物A,备用;将β-环糊精包合物A和浸膏细粉A混合均匀,加入β-环糊精包合物A和浸膏细粉A总重量28%-35%的糊精,混合均匀,加入体积浓度为79%的乙醇,加入乙醇量为β-环糊精包合物A、浸膏细粉A和糊精总重量的13%-17%,混匀,制粒,干燥,即得。
本发明原料丰富,制备方法科学、先进,引入了闪式提取及生物酶解的方法,大大缩短了提取所用时间,提高了提取效率,降低了生产能耗;提取所用乙醇经减压回收后可重复利用,因此本发明除解决了上述技术问题外,还有节约能耗,无污染排放的优点。本发明中药颗粒具有较好的温肺化饮功效,有效用于治疗感冒后咳嗽寒饮伏肺证,是中药上的创新。
四、具体实施方式
以下结合实施例对本发明的具体实施方式作进一步详细说明。
实施例1
本发明在具体实施中,本发明中药颗粒由麻黄31g、桂枝29g、桔梗31g、麦冬30g、芍药21g、甘草20g、清半夏22g、五味子16g、乌梅15g、银柴胡15g、防风14g制成;其中将麻黄粉碎成过20目筛的粗粉,加入麻黄8倍重量的pH为3.6的体积浓度为30%的乙醇溶液,65℃闪式提取3.3min,过滤,得药渣a和滤液a,备用;将桂枝、防风混合,粉碎成过20目筛的粗粉,加入桂枝、防风总重量8.7倍量的饮用水蒸馏4.8h,收集挥发油A备用,剩余蒸馏母液部分过滤得药渣b及滤液b备用;将桔梗、麦冬、芍药、甘草、五味子混合,粉碎成过20目筛的粗粉,加入体积浓度为65%的乙醇83℃回流提取2次,每次加入体积浓度为65%的乙醇的量为桔梗、麦冬、芍药、甘草、五味子总重量的7.6倍量,过滤,合并两次滤液,得药渣c及滤液c备用;将清半夏、乌梅、银柴胡及药渣a、药渣b、药渣c混合,加入清半夏、乌梅、银柴胡总重量8.8倍量的质量浓度为1.6%的纤维素酶溶液及清半夏、乌梅、银柴胡总重量5.8倍量的质量浓度为1.9%的果胶酶溶液,45℃浸泡50min,53℃酶解2.2h,94℃回流提取2.3h,过滤,得药渣d和滤液d备用;将药渣d加入清半夏、乌梅、银柴胡总重量6.1倍量的体积浓度为50%的乙醇76℃回流提取1.6h,过滤,弃去药渣,得滤液e备用;将滤液a以1mol/L的NaOH溶液调节pH至6.7,过滤,得滤液f,将滤液f与滤液b、滤液d合并,55℃减压浓缩至50℃时比重为1.26的浸膏,得浸膏Ⅰ,备用;将滤液c与滤液e合并,52℃减压回收乙醇,56℃减压浓缩至50℃时比重为1.29的浸膏,得浸膏II,备用;将浸膏Ⅰ、浸膏II合并混匀,50℃减压干燥,粉碎,得浸膏细粉A,备用;将挥发油A与挥发油A3.9倍重量的β-环糊精研磨包合,减压干燥,粉碎成细粉,得β-环糊精包合物A,备用;将β-环糊精包合物A和浸膏细粉A混合均匀,加入β-环糊精包合物A和浸膏细粉A总重量35%的糊精,混合均匀,加入体积浓度为79%的乙醇,加入乙醇量为β-环糊精包合物A、浸膏细粉A和糊精总重量的17%,混匀,制粒,干燥,即得。
实施例2
本发明在具体实施中,本发明中药颗粒由麻黄15g、桂枝15g、桔梗15g、麦冬15g、芍药12g、甘草12g、清半夏11g、五味子10g、乌梅10g、银柴胡9g、防风9g制成;其中将麻黄粉碎成过20目筛的粗粉,加入麻黄8倍重量的pH为3.6的体积浓度为30%的乙醇溶液,65℃闪式提取3.3min,过滤,得药渣a和滤液a,备用;将桂枝、防风混合,粉碎成过20目筛的粗粉,加入桂枝、防风总重量8.7倍量的饮用水蒸馏4.8h,收集挥发油A备用,剩余蒸馏母液部分过滤得药渣b及滤液b备用;将桔梗、麦冬、芍药、甘草、五味子混合,粉碎成过20目筛的粗粉,加入体积浓度为65%的乙醇83℃回流提取2次,每次加入体积浓度为65%的乙醇的量为桔梗、麦冬、芍药、甘草、五味子总重量的7.6倍量,过滤,合并两次滤液,得药渣c及滤液c备用;将清半夏、乌梅、银柴胡及药渣a、药渣b、药渣c混合,加入清半夏、乌梅、银柴胡总重量8.8倍量的质量浓度为1.6%的纤维素酶溶液及清半夏、乌梅、银柴胡总重量5.8倍量的质量浓度为1.9%的果胶酶溶液,45℃浸泡50min,53℃酶解2.2h,94℃回流提取2.3h,过滤,得药渣d和滤液d备用;将药渣d加入清半夏、乌梅、银柴胡总重量6.1倍量的体积浓度为50%的乙醇76℃回流提取1.6h,过滤,弃去药渣,得滤液e备用;将滤液a以1mol/L的NaOH溶液调节pH至6.7,过滤,得滤液f,将滤液f与滤液b、滤液d合并,55℃减压浓缩至50℃时比重为1.19的浸膏,得浸膏Ⅰ,备用;将滤液c与滤液e合并,52℃减压回收乙醇,56℃减压浓缩至50℃时比重为1.21的浸膏,得浸膏II,备用;将浸膏Ⅰ、浸膏II合并混匀,50℃减压干燥,粉碎,得浸膏细粉A,备用;将挥发油A与挥发油A3.9倍重量的β-环糊精研磨包合,减压干燥,粉碎成细粉,得β-环糊精包合物A,备用;将β-环糊精包合物A和浸膏细粉A混合均匀,加入β-环糊精包合物A和浸膏细粉A总重量28%的糊精,混合均匀,加入体积浓度为79%的乙醇,加入乙醇量为β-环糊精包合物A、浸膏细粉A和糊精总重量的13%,混匀,制粒,干燥,即得。
实施例3
本发明在具体实施中,本发明中药颗粒由麻黄23g、桂枝22g、桔梗23g、麦冬22g、芍药16g、甘草16g、清半夏16g、五味子13g、乌梅13g、银柴胡12g、防风12g制成;其中将麻黄粉碎成过20目筛的粗粉,加入麻黄8倍重量的pH为3.6的体积浓度为30%的乙醇溶液,65℃闪式提取3.3min,过滤,得药渣a和滤液a,备用;将桂枝、防风混合,粉碎成过20目筛的粗粉,加入桂枝、防风总重量8.7倍量的饮用水蒸馏4.8h,收集挥发油A备用,剩余蒸馏母液部分过滤得药渣b及滤液b备用;将桔梗、麦冬、芍药、甘草、五味子混合,粉碎成过20目筛的粗粉,加入体积浓度为65%的乙醇83℃回流提取2次,每次加入体积浓度为65%的乙醇的量为桔梗、麦冬、芍药、甘草、五味子总重量的7.6倍量,过滤,合并两次滤液,得药渣c及滤液c备用;将清半夏、乌梅、银柴胡及药渣a、药渣b、药渣c混合,加入清半夏、乌梅、银柴胡总重量8.8倍量的质量浓度为1.6%的纤维素酶溶液及清半夏、乌梅、银柴胡总重量5.8倍量的质量浓度为1.9%的果胶酶溶液,45℃浸泡50min,53℃酶解2.2h,94℃回流提取2.3h,过滤,得药渣d和滤液d备用;将药渣d加入清半夏、乌梅、银柴胡总重量6.1倍量的体积浓度为50%的乙醇76℃回流提取1.6h,过滤,弃去药渣,得滤液e备用;将滤液a以1mol/L的NaOH溶液调节pH至6.7,过滤,得滤液f,将滤液f与滤液b、滤液d合并,55℃减压浓缩至50℃时比重为1.22的浸膏,得浸膏Ⅰ,备用;将滤液c与滤液e合并,52℃减压回收乙醇,56℃减压浓缩至50℃时比重为1.25的浸膏,得浸膏II,备用;将浸膏Ⅰ、浸膏II合并混匀,50℃减压干燥,粉碎,得浸膏细粉A,备用;将挥发油A与挥发油A3.9倍重量的β-环糊精研磨包合,减压干燥,粉碎成细粉,得β-环糊精包合物A,备用;将β-环糊精包合物A和浸膏细粉A混合均匀,加入β-环糊精包合物A和浸膏细粉A总重量31%的糊精,混合均匀,加入体积浓度为79%的乙醇,加入乙醇量为β-环糊精包合物A、浸膏细粉A和糊精总重量的15%,混匀,制粒,干燥,即得。
实施例4
本发明在具体实施中,本发明中药颗粒由麻黄31g、桂枝15g、桔梗23g、麦冬30g、芍药12g、甘草16g、清半夏22g、五味子16g、乌梅10g、银柴胡9g、防风12g制成;其中将麻黄粉碎成过20目筛的粗粉,加入麻黄8倍重量的pH为3.6的体积浓度为30%的乙醇溶液,65℃闪式提取3.3min,过滤,得药渣a和滤液a,备用;将桂枝、防风混合,粉碎成过20目筛的粗粉,加入桂枝、防风总重量8.7倍量的饮用水蒸馏4.8h,收集挥发油A备用,剩余蒸馏母液部分过滤得药渣b及滤液b备用;将桔梗、麦冬、芍药、甘草、五味子混合,粉碎成过20目筛的粗粉,加入体积浓度为65%的乙醇83℃回流提取2次,每次加入体积浓度为65%的乙醇的量为桔梗、麦冬、芍药、甘草、五味子总重量的7.6倍量,过滤,合并两次滤液,得药渣c及滤液c备用;将清半夏、乌梅、银柴胡及药渣a、药渣b、药渣c混合,加入清半夏、乌梅、银柴胡总重量8.8倍量的质量浓度为1.6%的纤维素酶溶液及清半夏、乌梅、银柴胡总重量5.8倍量的质量浓度为1.9%的果胶酶溶液,45℃浸泡50min,53℃酶解2.2h,94℃回流提取2.3h,过滤,得药渣d和滤液d备用;将药渣d加入清半夏、乌梅、银柴胡总重量6.1倍量的体积浓度为50%的乙醇76℃回流提取1.6h,过滤,弃去药渣,得滤液e备用;将滤液a以1mol/L的NaOH溶液调节pH至6.7,过滤,得滤液f,将滤液f与滤液b、滤液d合并,55℃减压浓缩至50℃时比重为1.22的浸膏,得浸膏Ⅰ,备用;将滤液c与滤液e合并,52℃减压回收乙醇,56℃减压浓缩至50℃时比重为1.21的浸膏,得浸膏II,备用;将浸膏Ⅰ、浸膏II合并混匀,50℃减压干燥,粉碎,得浸膏细粉A,备用;将挥发油A与挥发油A3.9倍重量的β-环糊精研磨包合,减压干燥,粉碎成细粉,得β-环糊精包合物A,备用;将β-环糊精包合物A和浸膏细粉A混合均匀,加入β-环糊精包合物A和浸膏细粉A总重量35%的糊精,混合均匀,加入体积浓度为79%的乙醇,加入乙醇量为β-环糊精包合物A、浸膏细粉A和糊精总重量的13%,混匀,制粒,干燥,即得。
根据中医药学原理,认为本病的发病原因为外感六淫犯肺,内伤脏腑受损,即本肺系疾病感冒后咳嗽由外感风寒之邪引发,继而外感发为感冒,感冒不愈引起脏腑阴或阳的亏虚或损伤,而发为内伤咳嗽。其病位在肺,病因主要是外感与内伤。
感冒后咳嗽中医辩证上分为:风寒表证、寒饮伏肺证、痰湿阻肺证、肺脾两虚证、肺肾阳虚证。感冒后咳嗽,咳嗽,怕冷,肺气上逆,容易有喘促的感觉,气短,有痰,痰色清稀,此为寒饮伏肺证。
本研究主要纳入寒饮伏肺证:主症:咳嗽,怕冷,肺气上逆,气短,痰白清稀;次症:咽痒,口不干渴,鼻塞,流清涕,小便清长,舌淡苔薄白或白腻,脉浮紧或滑。
为了证明本发明中药颗粒能够有效用于治疗感冒后咳嗽寒饮伏肺证,并具有有效的效果,进行了临床验证实验,具体如下:
(一)诊断标准
1.西医诊断标准 参照中华医学会呼吸病学分会哮喘学组制定的《咳嗽的诊断与治疗指南》中的诊断标准制定。
(l)具有近期呼吸道感染病史;
(2)感染急性期症状消退后,咳嗽仍然迁延不愈甚至加剧,临床表现以咳嗽、咽痒为主,咳嗽可表现为干咳或咳白色粘液痰,抗生素治疗无明显效果,时间常持续3-8周;
(3)体征及辅助检查:两肺未闻及干湿性啰音,血常规及X线胸片无明显异常;
(4)排除其他原因引起的咳嗽,如胃食管返流性咳嗽、嗜酸细胞性支气管炎等。
2.中医诊断标准:根据《中医内科学》及《中医诊断学》(人民卫生出版社,2002)中的外感咳嗽证型标准制定。
寒饮伏肺证:主症:咳嗽,怕冷,肺气上逆,气短,痰白清稀;次症:咽痒,口不干渴,鼻塞,流清涕,小便清长,舌淡苔薄白或白腻,脉浮紧或滑。
(二)纳入标准
(1)符合西医感冒后咳嗽诊断标准。
(2)符合中医证候寒饮伏肺证诊断标准。
(3)年龄大于18周岁。
(4)知情同意,志愿受试。
(三)病例临床选取标准
选取符合西医诊断标准感冒后咳嗽诊断标准及临床表现和中医寒饮伏肺证诊断标准的患者进行临床研究。选取的感冒后咳嗽寒饮伏肺证患者随机分为治疗组与对照组,治疗组63例,男34例,女29例;对照组63例,男36例,女27例;两组在年龄、病程、治疗前寒饮伏肺证评分方面均无显著性差异(P>0.05)。
(四)治疗方案
在本试验研究前2个月内,研究进行期间尽可能排除影响临床疗效观察的相关药物和治疗方法。
1.治疗组:给予本发明中药颗粒,每日3次,每次1包,每包重量10g,冲服,连续治疗2周为1个疗程。
2.对照组:给予美敏伪麻溶液(规格:100mL/瓶,由惠氏-百宫制药有限公司生产,国药准字H20030051),口服,每次10ml,每日3次,连续治疗2周为1个疗程。
3.中医寒饮伏肺证评分标准
参照《中医内科学》及《中药新药临床研究指导原则》对感冒后咳嗽患者寒饮伏肺证进行评分,各证每项0~10分,分值越高,表示症状越严重。
4.疾病疗效判断标准
参照《中华人民共和国中医药行业标准》、《中药新药临床研究指导原则》及《中医病症诊断疗效标准》中的有关论述制定。
①治愈:咳嗽及临床体征均消失,2周以上未复发;
②显效:咳嗽及临床体征基本消失;
③有效:咳嗽及临床体征有所减轻;
④无效:治疗后症状体征无明显变化或有加重。
(五)临床疗效统计
表1总体疗效比较
*与对照组比较P<0.05
*与对照组比较P<0.05;**与对照组比较P<0.01
(六)结论
临床实验表明,本发明治疗感冒后咳嗽寒饮伏肺证的中药颗粒使用安全有效,对感冒后咳嗽寒饮伏肺证的临床治疗总有效率达到92.06%,显著优于西药对照组(P<0.05);本发明中药颗粒对感冒后咳嗽寒饮伏肺证的积分改善情况显著优于西药对照组(P<0.05),是治疗感冒后咳嗽寒饮伏肺证中药颗粒上的创新,具有疗效确切,方便易行,患者接受度较高,副作用少等优点,具有实际的临床意义和广泛的推广应用价值。
Claims (7)
1.一种治疗感冒后咳嗽寒饮伏肺证的中药颗粒,其特征在于,该中药颗粒是由麻黄、桂枝、桔梗、麦冬、芍药、甘草、清半夏、五味子、乌梅、银柴胡、防风制成;各种原料药的重量份为:麻黄15-31、桂枝15-29、桔梗15-31、麦冬15-30、芍药12-21、甘草12-20、清半夏11-22、五味子10-16、乌梅10-15、银柴胡9-15、防风9-14;其中将麻黄粉碎成过20目筛的粗粉,加入麻黄8倍重量的pH为3.6的体积浓度为30%的乙醇溶液,65℃闪式提取3.3min,过滤,得药渣a和滤液a,备用;将桂枝、防风混合,粉碎成过20目筛的粗粉,加入桂枝、防风总重量8.7倍量的饮用水蒸馏4.8h,收集挥发油A备用,剩余蒸馏母液部分过滤得药渣b及滤液b备用;将桔梗、麦冬、芍药、甘草、五味子混合,粉碎成过20目筛的粗粉,加入体积浓度为65%的乙醇83℃回流提取2次,每次加入体积浓度为65%的乙醇的量为桔梗、麦冬、芍药、甘草、五味子总重量的7.6倍量,过滤,合并两次滤液,得药渣c及滤液c备用;将清半夏、乌梅、银柴胡及药渣a、药渣b、药渣c混合,加入清半夏、乌梅、银柴胡总重量8.8倍量的质量浓度为1.6%的纤维素酶溶液及清半夏、乌梅、银柴胡总重量5.8倍量的质量浓度为1.9%的果胶酶溶液,45℃浸泡50min,53℃酶解2.2h,94℃回流提取2.3h,过滤,得药渣d和滤液d备用;将药渣d加入清半夏、乌梅、银柴胡总重量6.1倍量的体积浓度为50%的乙醇76℃回流提取1.6h,过滤,弃去药渣,得滤液e备用;将滤液a以1mol/L的NaOH溶液调节pH至6.7,过滤,得滤液f,将滤液f与滤液b、滤液d合并,55℃减压浓缩至50℃时比重为1.19-1.26的浸膏,得浸膏Ⅰ,备用;将滤液c与滤液e合并,52℃减压回收乙醇,56℃减压浓缩至50℃时比重为1.21-1.29的浸膏,得浸膏Ⅱ,备用;将浸膏Ⅰ、浸膏Ⅱ合并混匀,50℃减压干燥,粉碎,得浸膏细粉A,备用;将挥发油A与挥发油A3.9倍重量的β-环糊精研磨包合,减压干燥,粉碎成细粉,得β-环糊精包合物A,备用;将β-环糊精包合物A和浸膏细粉A混合均匀,加入β-环糊精包合物A和浸膏细粉A总重量28%-35%的糊精,混合均匀,加入体积浓度为79%的乙醇,加入乙醇量为β-环糊精包合物A、浸膏细粉A和糊精总重量的13%-17%,混匀,制粒,干燥,即得。
2.根据权利要求1所述的一种治疗感冒后咳嗽寒饮伏肺证的中药颗粒,其特征在于,该中药颗粒是由以下重量计的原料药物制成:麻黄15-31g、桂枝15-29g、桔梗15-31g、麦冬15-30g、芍药12-21g、甘草12-20g、清半夏11-22g、五味子10-16g、乌梅10-15g、银柴胡9-15g、防风9-14g;其中将麻黄粉碎成过20目筛的粗粉,加入麻黄8倍重量的pH为3.6的体积浓度为30%的乙醇溶液,65℃闪式提取3.3min,过滤,得药渣a和滤液a,备用;将桂枝、防风混合,粉碎成过20目筛的粗粉,加入桂枝、防风总重量8.7倍量的饮用水蒸馏4.8h,收集挥发油A备用,剩余蒸馏母液部分过滤得药渣b及滤液b备用;将桔梗、麦冬、芍药、甘草、五味子混合,粉碎成过20目筛的粗粉,加入体积浓度为65%的乙醇83℃回流提取2次,每次加入体积浓度为65%的乙醇的量为桔梗、麦冬、芍药、甘草、五味子总重量的7.6倍量,过滤,合并两次滤液,得药渣c及滤液c备用;将清半夏、乌梅、银柴胡及药渣a、药渣b、药渣c混合,加入清半夏、乌梅、银柴胡总重量8.8倍量的质量浓度为1.6%的纤维素酶溶液及清半夏、乌梅、银柴胡总重量5.8倍量的质量浓度为1.9%的果胶酶溶液,45℃浸泡50min,53℃酶解2.2h,94℃回流提取2.3h,过滤,得药渣d和滤液d备用;将药渣d加入清半夏、乌梅、银柴胡总重量6.1倍量的体积浓度为50%的乙醇76℃回流提取1.6h,过滤,弃去药渣,得滤液e备用;将滤液a以1mol/L的NaOH溶液调节pH至6.7,过滤,得滤液f,将滤液f与滤液b、滤液d合并,55℃减压浓缩至50℃时比重为1.19-1.26的浸膏,得浸膏Ⅰ,备用;将滤液c与滤液e合并,52℃减压回收乙醇,56℃减压浓缩至50℃时比重为1.21-1.29的浸膏,得浸膏Ⅱ,备用;将浸膏Ⅰ、浸膏Ⅱ合并混匀,50℃减压干燥,粉碎,得浸膏细粉A,备用;将挥发油A与挥发油A3.9倍重量的β-环糊精研磨包合,减压干燥,粉碎成细粉,得β-环糊精包合物A,备用;将β-环糊精包合物A和浸膏细粉A混合均匀,加入β-环糊精包合物A和浸膏细粉A总重量28%-35%的糊精,混合均匀,加入体积浓度为79%的乙醇,加入乙醇量为β-环糊精包合物A、浸膏细粉A和糊精总重量的13%-17%,混匀,制粒,干燥,即得。
3.根据权利要求1所述的一种治疗感冒后咳嗽寒饮伏肺证的中药颗粒,其特征在于,该中药颗粒是由以下重量计的原料药物制成:麻黄31g、桂枝29g、桔梗31g、麦冬30g、芍药21g、甘草20g、清半夏22g、五味子16g、乌梅15g、银柴胡15g、防风14g;其中将麻黄粉碎成过20目筛的粗粉,加入麻黄8倍重量的pH为3.6的体积浓度为30%的乙醇溶液,65℃闪式提取3.3min,过滤,得药渣a和滤液a,备用;将桂枝、防风混合,粉碎成过20目筛的粗粉,加入桂枝、防风总重量8.7倍量的饮用水蒸馏4.8h,收集挥发油A备用,剩余蒸馏母液部分过滤得药渣b及滤液b备用;将桔梗、麦冬、芍药、甘草、五味子混合,粉碎成过20目筛的粗粉,加入体积浓度为65%的乙醇83℃回流提取2次,每次加入体积浓度为65%的乙醇的量为桔梗、麦冬、芍药、甘草、五味子总重量的7.6倍量,过滤,合并两次滤液,得药渣c及滤液c备用;将清半夏、乌梅、银柴胡及药渣a、药渣b、药渣c混合,加入清半夏、乌梅、银柴胡总重量8.8倍量的质量浓度为1.6%的纤维素酶溶液及清半夏、乌梅、银柴胡总重量5.8倍量的质量浓度为1.9%的果胶酶溶液,45℃浸泡50min,53℃酶解2.2h,94℃回流提取2.3h,过滤,得药渣d和滤液d备用;将药渣d加入清半夏、乌梅、银柴胡总重量6.1倍量的体积浓度为50%的乙醇76℃回流提取1.6h,过滤,弃去药渣,得滤液e备用;将滤液a以1mol/L的NaOH溶液调节pH至6.7,过滤,得滤液f,将滤液f与滤液b、滤液d合并,55℃减压浓缩至50℃时比重为1.26的浸膏,得浸膏Ⅰ,备用;将滤液c与滤液e合并,52℃减压回收乙醇,56℃减压浓缩至50℃时比重为1.29的浸膏,得浸膏Ⅱ,备用;将浸膏Ⅰ、浸膏Ⅱ合并混匀,50℃减压干燥,粉碎,得浸膏细粉A,备用;将挥发油A与挥发油A3.9倍重量的β-环糊精研磨包合,减压干燥,粉碎成细粉,得β-环糊精包合物A,备用;将β-环糊精包合物A和浸膏细粉A混合均匀,加入β-环糊精包合物A和浸膏细粉A总重量35%的糊精,混合均匀,加入体积浓度为79%的乙醇,加入乙醇量为β-环糊精包合物A、浸膏细粉A和糊精总重量的17%,混匀,制粒,干燥,即得。
4.根据权利要求1所述的一种治疗感冒后咳嗽寒饮伏肺证的中药颗粒,其特征在于,该中药颗粒是由以下重量计的原料药物制成:麻黄15g、桂枝15g、桔梗15g、麦冬15g、芍药12g、甘草12g、清半夏11g、五味子10g、乌梅10g、银柴胡9g、防风9g;其中将麻黄粉碎成过20目筛的粗粉,加入麻黄8倍重量的pH为3.6的体积浓度为30%的乙醇溶液,65℃闪式提取3.3min,过滤,得药渣a和滤液a,备用;将桂枝、防风混合,粉碎成过20目筛的粗粉,加入桂枝、防风总重量8.7倍量的饮用水蒸馏4.8h,收集挥发油A备用,剩余蒸馏母液部分过滤得药渣b及滤液b备用;将桔梗、麦冬、芍药、甘草、五味子混合,粉碎成过20目筛的粗粉,加入体积浓度为65%的乙醇83℃回流提取2次,每次加入体积浓度为65%的乙醇的量为桔梗、麦冬、芍药、甘草、五味子总重量的7.6倍量,过滤,合并两次滤液,得药渣c及滤液c备用;将清半夏、乌梅、银柴胡及药渣a、药渣b、药渣c混合,加入清半夏、乌梅、银柴胡总重量8.8倍量的质量浓度为1.6%的纤维素酶溶液及清半夏、乌梅、银柴胡总重量5.8倍量的质量浓度为1.9%的果胶酶溶液,45℃浸泡50min,53℃酶解2.2h,94℃回流提取2.3h,过滤,得药渣d和滤液d备用;将药渣d加入清半夏、乌梅、银柴胡总重量6.1倍量的体积浓度为50%的乙醇76℃回流提取1.6h,过滤,弃去药渣,得滤液e备用;将滤液a以1mol/L的NaOH溶液调节pH至6.7,过滤,得滤液f,将滤液f与滤液b、滤液d合并,55℃减压浓缩至50℃时比重为1.19的浸膏,得浸膏Ⅰ,备用;将滤液c与滤液e合并,52℃减压回收乙醇,56℃减压浓缩至50℃时比重为1.21的浸膏,得浸膏Ⅱ,备用;将浸膏Ⅰ、浸膏Ⅱ合并混匀,50℃减压干燥,粉碎,得浸膏细粉A,备用;将挥发油A与挥发油A3.9倍重量的β-环糊精研磨包合,减压干燥,粉碎成细粉,得β-环糊精包合物A,备用;将β-环糊精包合物A和浸膏细粉A混合均匀,加入β-环糊精包合物A和浸膏细粉A总重量28%的糊精,混合均匀,加入体积浓度为79%的乙醇,加入乙醇量为β-环糊精包合物A、浸膏细粉A和糊精总重量的13%,混匀,制粒,干燥,即得。
5.根据权利要求1所述的一种治疗感冒后咳嗽寒饮伏肺证的中药颗粒,其特征在于,该中药颗粒是由以下重量计的原料药物制成:麻黄23g、桂枝22g、桔梗23g、麦冬22g、芍药16g、甘草16g、清半夏16g、五味子13g、乌梅13g、银柴胡12g、防风12g;其中将麻黄粉碎成过20目筛的粗粉,加入麻黄8倍重量的pH为3.6的体积浓度为30%的乙醇溶液,65℃闪式提取3.3min,过滤,得药渣a和滤液a,备用;将桂枝、防风混合,粉碎成过20目筛的粗粉,加入桂枝、防风总重量8.7倍量的饮用水蒸馏4.8h,收集挥发油A备用,剩余蒸馏母液部分过滤得药渣b及滤液b备用;将桔梗、麦冬、芍药、甘草、五味子混合,粉碎成过20目筛的粗粉,加入体积浓度为65%的乙醇83℃回流提取2次,每次加入体积浓度为65%的乙醇的量为桔梗、麦冬、芍药、甘草、五味子总重量的7.6倍量,过滤,合并两次滤液,得药渣c及滤液c备用;将清半夏、乌梅、银柴胡及药渣a、药渣b、药渣c混合,加入清半夏、乌梅、银柴胡总重量8.8倍量的质量浓度为1.6%的纤维素酶溶液及清半夏、乌梅、银柴胡总重量5.8倍量的质量浓度为1.9%的果胶酶溶液,45℃浸泡50min,53℃酶解2.2h,94℃回流提取2.3h,过滤,得药渣d和滤液d备用;将药渣d加入清半夏、乌梅、银柴胡总重量6.1倍量的体积浓度为50%的乙醇76℃回流提取1.6h,过滤,弃去药渣,得滤液e备用;将滤液a以1mol/L的NaOH溶液调节pH至6.7,过滤,得滤液f,将滤液f与滤液b、滤液d合并,55℃减压浓缩至50℃时比重为1.22的浸膏,得浸膏Ⅰ,备用;将滤液c与滤液e合并,52℃减压回收乙醇,56℃减压浓缩至50℃时比重为1.25的浸膏,得浸膏Ⅱ,备用;将浸膏Ⅰ、浸膏Ⅱ合并混匀,50℃减压干燥,粉碎,得浸膏细粉A,备用;将挥发油A与挥发油A3.9倍重量的β-环糊精研磨包合,减压干燥,粉碎成细粉,得β-环糊精包合物A,备用;将β-环糊精包合物A和浸膏细粉A混合均匀,加入β-环糊精包合物A和浸膏细粉A总重量31%的糊精,混合均匀,加入体积浓度为79%的乙醇,加入乙醇量为β-环糊精包合物A、浸膏细粉A和糊精总重量的15%,混匀,制粒,干燥,即得。
6.根据权利要求1所述的一种治疗感冒后咳嗽寒饮伏肺证的中药颗粒,其特征在于,该中药颗粒是由以下重量计的原料药物制成:麻黄31g、桂枝15g、桔梗23g、麦冬30g、芍药12g、甘草16g、清半夏22g、五味子16g、乌梅10g、银柴胡9g、防风12g;其中将麻黄粉碎成过20目筛的粗粉,加入麻黄8倍重量的pH为3.6的体积浓度为30%的乙醇溶液,65℃闪式提取3.3min,过滤,得药渣a和滤液a,备用;将桂枝、防风混合,粉碎成过20目筛的粗粉,加入桂枝、防风总重量8.7倍量的饮用水蒸馏4.8h,收集挥发油A备用,剩余蒸馏母液部分过滤得药渣b及滤液b备用;将桔梗、麦冬、芍药、甘草、五味子混合,粉碎成过20目筛的粗粉,加入体积浓度为65%的乙醇83℃回流提取2次,每次加入体积浓度为65%的乙醇的量为桔梗、麦冬、芍药、甘草、五味子总重量的7.6倍量,过滤,合并两次滤液,得药渣c及滤液c备用;将清半夏、乌梅、银柴胡及药渣a、药渣b、药渣c混合,加入清半夏、乌梅、银柴胡总重量8.8倍量的质量浓度为1.6%的纤维素酶溶液及清半夏、乌梅、银柴胡总重量5.8倍量的质量浓度为1.9%的果胶酶溶液,45℃浸泡50min,53℃酶解2.2h,94℃回流提取2.3h,过滤,得药渣d和滤液d备用;将药渣d加入清半夏、乌梅、银柴胡总重量6.1倍量的体积浓度为50%的乙醇76℃回流提取1.6h,过滤,弃去药渣,得滤液e备用;将滤液a以1mol/L的NaOH溶液调节pH至6.7,过滤,得滤液f,将滤液f与滤液b、滤液d合并,55℃减压浓缩至50℃时比重为1.22的浸膏,得浸膏Ⅰ,备用;将滤液c与滤液e合并,52℃减压回收乙醇,56℃减压浓缩至50℃时比重为1.21的浸膏,得浸膏Ⅱ,备用;将浸膏Ⅰ、浸膏Ⅱ合并混匀,50℃减压干燥,粉碎,得浸膏细粉A,备用;将挥发油A与挥发油A3.9倍重量的β-环糊精研磨包合,减压干燥,粉碎成细粉,得β-环糊精包合物A,备用;将β-环糊精包合物A和浸膏细粉A混合均匀,加入β-环糊精包合物A和浸膏细粉A总重量35%的糊精,混合均匀,加入体积浓度为79%的乙醇,加入乙醇量为β-环糊精包合物A、浸膏细粉A和糊精总重量的13%,混匀,制粒,干燥,即得。
7.权利要求1或2-6任一项所述的治疗感冒后咳嗽寒饮伏肺证的中药颗粒,在制备治疗感冒后咳嗽寒饮伏肺证药物中的应用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010030454.9A CN111035716A (zh) | 2020-01-13 | 2020-01-13 | 一种治疗感冒后咳嗽寒饮伏肺证的中药颗粒 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010030454.9A CN111035716A (zh) | 2020-01-13 | 2020-01-13 | 一种治疗感冒后咳嗽寒饮伏肺证的中药颗粒 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN111035716A true CN111035716A (zh) | 2020-04-21 |
Family
ID=70244458
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010030454.9A Pending CN111035716A (zh) | 2020-01-13 | 2020-01-13 | 一种治疗感冒后咳嗽寒饮伏肺证的中药颗粒 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN111035716A (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115990220A (zh) * | 2022-12-02 | 2023-04-21 | 史利卿 | 一种止咳的中药组合物及其应用、治疗咳嗽寒饮伏肺证的颗粒剂及其制备方法 |
CN116920041A (zh) * | 2023-04-10 | 2023-10-24 | 咸宁市中心医院 | 一种防治新型冠状病毒感染的中药组合物及其应用 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104758874A (zh) * | 2015-03-18 | 2015-07-08 | 梁晓 | 一种治疗外寒内饮型慢性支气管炎的中药组合物 |
CN107617087A (zh) * | 2016-07-14 | 2018-01-23 | 王涛 | 小青龙汤的中药制剂 |
CN109985166A (zh) * | 2019-05-20 | 2019-07-09 | 河南中医药大学 | 一种治疗过敏性鼻炎的中药颗粒 |
-
2020
- 2020-01-13 CN CN202010030454.9A patent/CN111035716A/zh active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104758874A (zh) * | 2015-03-18 | 2015-07-08 | 梁晓 | 一种治疗外寒内饮型慢性支气管炎的中药组合物 |
CN107617087A (zh) * | 2016-07-14 | 2018-01-23 | 王涛 | 小青龙汤的中药制剂 |
CN109985166A (zh) * | 2019-05-20 | 2019-07-09 | 河南中医药大学 | 一种治疗过敏性鼻炎的中药颗粒 |
Non-Patent Citations (3)
Title |
---|
张瑞明: ""苏日克老师中医药治疗咳嗽变异性哮喘经验"", 《内蒙古中医药》 * |
王四平: "《平脉辨证三年跟师记》", 30 April 2013, 中国中医药出版社 * |
缪勇等: "《中草药植物提取与深加工新技术实用手册 第2卷》", 30 April 2004, 天津电子出版社 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115990220A (zh) * | 2022-12-02 | 2023-04-21 | 史利卿 | 一种止咳的中药组合物及其应用、治疗咳嗽寒饮伏肺证的颗粒剂及其制备方法 |
CN116920041A (zh) * | 2023-04-10 | 2023-10-24 | 咸宁市中心医院 | 一种防治新型冠状病毒感染的中药组合物及其应用 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN111035716A (zh) | 一种治疗感冒后咳嗽寒饮伏肺证的中药颗粒 | |
CN109260340A (zh) | 一种中药组合物及其制备方法及应用 | |
CN109908194B (zh) | 一种用于治疗急慢性咽炎的药物及其制备方法 | |
CN111068034A (zh) | 一种治疗感冒后咳嗽寒饮伏肺证的中药外用贴剂 | |
CN115919963A (zh) | 一种中药组合物在制备治疗新型冠状病毒感染药物中的应用 | |
CN102397458B (zh) | 一种治疗老年人肺炎的药物组合物及其制备方法 | |
CN106310017A (zh) | 一种治疗弥漫性肺间质纤维化肺肾气虚证的中药颗粒 | |
CN106581520B (zh) | 一种治疗弥漫性肺间质纤维化肺气虚证的中药颗粒 | |
CN106880654B (zh) | 竹节参提取物在制备治疗鼻炎药物中的应用及组合物 | |
CN107714820B (zh) | 一种治疗过敏性鼻炎的药物组合物及其制备方法和用途 | |
CN102274428B (zh) | 一种具有治疗肠易激综合症作用的药物组合物及其制备方法和应用 | |
CN110946950A (zh) | 一种治疗老年期血管性痴呆的中药组合物及其制备方法 | |
CN111068014A (zh) | 一种治疗过敏性鼻炎水寒射肺证的中药颗粒 | |
CN117257866B (zh) | 一种治疗社区获得性肺炎的中药组合物和用途 | |
CN104606596B (zh) | 一种治疗贝赫切特病的中成药及其制备方法 | |
CN109568415B (zh) | 一种用于治疗过敏性鼻炎的药物组合物及其制备方法和用途 | |
CN111494508B (zh) | 一种中药痛风贴的制备方法及其产品 | |
CN116270922B (zh) | 化浊散结除痹方及其应用 | |
CN112138105B (zh) | 一种治疗支气管扩张症肺脾气虚、痰湿阻肺证的中药组合物及其应用 | |
CN115105480B (zh) | 一种藿香正气片及其制备方法 | |
CN116785393B (zh) | 一种治疗进展性肺纤维化的中药组合物及其应用 | |
CN106963833B (zh) | 一种治疗儿童及成人感冒的药物及其制备方法 | |
CN1634340A (zh) | 一种防治少儿呼吸系统疾病的药物组合物及其制备方法 | |
CN1562222A (zh) | 治疗肾病的药物及其制备方法 | |
CN105641048A (zh) | 一种治疗儿童手足口病的中药及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |